GlassScriptPhysician profile
Matthew Mossanen
NPI 1508180241
$13,686.22
in general payments reported to CMS, 2019-2025
10 companies · $3,249 in 2025
The $3,249 reported for 2025 was more than what 87% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,735 · 2023: $5,017 · 2024: $3,686 · 2025: $3,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,620 · Honoraria: $3,125 · Food and Beverage: $2,538 · Travel and Lodging: $1,633 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,620.00 |
| Honoraria | $3,125.00 |
| Food and Beverage | $2,537.91 |
| Travel and Lodging | $1,633.32 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $3,483.54 | 2024-2025 | |
| Medtronic, INC. | $2,974.93 | 2022-2023 | |
| Intuitive Surgical, INC. | $2,156.59 | 2023 | Da Vinci Surgical System, Da Vinci Sp |
| Astellas Pharma US INC | $1,938.14 | 2025 | Padcev |
| Olympus Medical Systems Corporation | $1,620.00 | 2023 | Oes Choledochofiberscope |
| Fennec Pharmaceuticals, INC. | $1,025.72 | 2024-2025 | Fyarro, Pedmark |
| Becton, Dickinson and Company | $418.91 | 2025 | Arista, Surgiphor |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Photocure INC | $33.33 | 2025 | Cysview |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mossanen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.